Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE
REGULATORY UPDATE ON OMAVELOXOLONE
YEAR 2 DATA FROM CARDINAL TRIAL EXPECTED IN FOURTH QUARTER 2020
ENROLLMENT RESUMED IN FALCON TRIAL
Regulatory Update
Bardoxolone Methyl (“Bardoxolone”) for Alport Syndrome
Since the announcement of positive, Year 1 data from the Phase 3 CARDINAL study, we have been engaged in discussions with the
One of the key questions to be resolved in the pre-NDA meeting is how the data from Year 2 of the CARDINAL study should be handled during the NDA review process. Our plan has been, and continues to be, to submit the NDA for bardoxolone in Alport syndrome during fourth quarter of 2020 for accelerated approval based on the one-year data from the Phase 3 portion of CARDINAL. If the second-year results are available during an acceptable time frame, we may be able to submit the second-year data to the NDA during the review process and before the FDA makes a determination about accelerated approval. This may extend the PDUFA date, but could also result in consideration of full approval, rather than accelerated approval. The FDA could recommend that we wait for the second-year data from CARDINAL to file the NDA. This would permit us to file for full approval but would delay the filing until the first quarter of 2021, compared to our current guidance of filing by the end of this year.
Omaveloxolone for Friedreich’s Ataxia
Following the announcement of the positive data from the MOXIe Part 2 study in
In response to the preliminary comments, the Friedreich’s
At the Type C meeting, to address the FDA’s requirement, FARA, key opinion leaders, and Reata proposed a second study (the “crossover study”) to provide additional evidence of effectiveness. The study would measure the effect of omaveloxolone on mFARS in patients who were previously randomized to placebo in the MOXIe Part 2 study and are being treated with omaveloxolone in the MOXIe open-label extension study. The FDA acknowledged that a study like the proposed crossover study could provide important additional information and asked us to submit a design for the crossover study for their consideration.
If the FDA accepts this approach, we expect to complete the crossover study as early as the fourth quarter of this year. Assuming that the FDA views the crossover study data as sufficiently positive to provide confirmatory evidence, our plan would be to submit an NDA during the first quarter of 2021. If the FDA rejects the proposal or if the data are not supportive, we will evaluate whether it is feasible to conduct a second pivotal study in FA patients as suggested by the FDA. Regardless of the interaction with the FDA, we plan to pursue marketing approval outside of
Clinical Development Update
CARDINAL Phase 3 Study of Bardoxolone in Alport Syndrome
We are in the process of completing the second year of CARDINAL and anticipate that the study will be completed this year. The last study visits are anticipated to occur during the fourth quarter of 2020, which is consistent with our pre-COVID-19 trial timeline. As a result of the measures taken in response to the pandemic, at this time we believe that the timeline for Year 2 data availability is unlikely to be affected by COVID-19.
FALCON Phase 3 Study of Bardoxolone in Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)
In
BARCONA Study of Bardoxolone in Patients with COVID-19
Reata recently announced the start of an investigator-sponsored trial, led by researchers at New York University’s (“NYU”)
Second Quarter Financial Highlights
Reata recently announced a strategic investment from Blackstone Life Sciences (“BXLS”) of
In connection with the closing of the BXLS investment, the Company paid off in full its senior loan with
Cash and Cash Equivalents
On
Collaboration Revenue
Collaboration Revenue was
R&D expenses according to generally accepted accounting principles in the
Non-GAAP R&D expenses were
GAAP and Non-GAAP General and Administrative (“G&A”) Expenses
GAAP G&A expenses were
Non-GAAP G&A expenses were
GAAP and Non-GAAP Net Loss
The GAAP net loss for the second quarter of 2020 was
The increase in GAAP net loss for the second quarter of 2020 is driven primarily by the loss on extinguishment of debt related to the payoff of our loan to
The non-GAAP net loss for the second quarter of 2020 was
Reiterates Cash Guidance
The Company reiterated that it expects existing cash and cash equivalents will be sufficient to enable it to fund operations through the end of 2023.
___________________________
1 See “Use of Non-GAAP Financial Measures” below for a description of non-GAAP financial measures and a reconciliation between GAAP and non-GAAP R&D expenses, GAAP and non-GAAP G&A expenses, and GAAP and non-GAAP net loss, respectively, appearing later in the press release.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP R&D expenses, non-GAAP G&A expenses, non-GAAP operating expenses, non-GAAP net loss and non-GAAP net loss per common share – basic and diluted. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The Company defines non-GAAP R&D expenses as GAAP R&D expenses less stock-based compensation expense; non-GAAP G&A expenses as GAAP G&A expenses less stock-based compensation expense; non-GAAP operating expenses as GAAP operating expenses less stock-based compensation expense; non-GAAP net loss as GAAP net loss plus stock-based compensation expense, loss on extinguishment of debt, and non-cash interest expense from liability related to sale of future royalties; and non-GAAP net loss per common share – basic and diluted as GAAP net loss per common share – basic and diluted plus stock-based compensation expense, loss on extinguishment of debt, and non-cash interest expense from liability related to sale of future royalties. During the three and six months ended
Because management believes certain items, such as stock-based compensation expense, loss on extinguishment of debt, non-cash interest expense from liability related to sales of future royalties, and reacquired license rights expense can distort the trends associated with the Company’s ongoing performance, the following measures are often provided, excluding special items, and utilized by the Company’s management, analysts, and investors to enhance consistency and comparability of year-over-year results, as well as to industry trends, and to provide a basis for evaluating operating results in future periods: non-GAAP net loss; non-GAAP net loss per common share – basic and diluted; non-GAAP R&D expenses; non-GAAP G&A expenses; and non-GAAP operating expenses.
The Company believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with these non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this press release.
Conference Call Information
Reata’s management will host a conference call on
Second quarter 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.
About
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Contact:
(972) 865-2219
http://reatapharma.com
Investors:
Vice President, Corporate Communications and Strategy
(469) 374-8721
ir@reatapharma.com
http://reatapharma.com/contact-us/
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the
Three Months Ended | Six Months Ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Consolidated Statements of Operations | (unaudited) | |||||||||||||||
(in thousands, except share and per share data) | ||||||||||||||||
Collaboration revenue | ||||||||||||||||
License and milestone | $ | 1,169 | $ | 7,813 | $ | 2,338 | $ | 15,539 | ||||||||
Other revenue | 1,904 | 20 | 2,088 | 64 | ||||||||||||
Total collaboration revenue | 3,073 | 7,833 | 4,426 | 15,603 | ||||||||||||
Expenses | ||||||||||||||||
Research and development | 36,783 | 29,554 | 84,436 | 55,668 | ||||||||||||
General and administrative | 16,600 | 11,706 | 37,387 | 21,744 | ||||||||||||
Depreciation | 284 | 232 | 562 | 401 | ||||||||||||
Total expenses | 53,667 | 41,492 | 122,385 | 77,813 | ||||||||||||
Other income (expense), net | (16,990 | ) | (701 | ) | (20,804 | ) | (1,301 | ) | ||||||||
Loss before taxes on income | (67,584 | ) | (34,360 | ) | (138,763 | ) | (63,511 | ) | ||||||||
(Benefit from) provision for taxes on income | (3 | ) | 20 | (22,243 | ) | 23 | ||||||||||
Net loss | $ | (67,581 | ) | $ | (34,380 | ) | $ | (116,520 | ) | $ | (63,534 | ) | ||||
Net loss per share—basic and diluted | $ | (2.03 | ) | $ | (1.14 | ) | $ | (3.51 | ) | $ | (2.12 | ) | ||||
Weighted-average number of common shares used in net loss per share basic and diluted |
33,265,778 | 30,069,048 | 33,243,931 | 29,950,241 | ||||||||||||
As of (unaudited) |
As of |
|||||||
(in thousands) | ||||||||
Condensed Consolidated Balance Sheet Data | ||||||||
Cash and cash equivalents | $ | 610,419 | $ | 664,324 | ||||
Working capital | 593,282 | 477,262 | ||||||
Total assets | 652,404 | 682,420 | ||||||
Term loan (including current portion, net of issuance cost) | – | 155,017 | ||||||
Liability related to sale of future royalties, net | 294,234 | – | ||||||
Payable to collaborators | 70,055 | 216,862 | ||||||
Deferred revenue (including current portion) | 7,051 | 9,389 | ||||||
Accumulated deficit | (827,013 | ) | (710,493 | ) | ||||
Total stockholders’ equity | $ | 231,627 | $ | 256,857 |
Reconciliation of GAAP to Non-GAAP Financial Measures
The following table presents reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures (in thousands, except for per share data) (unaudited):
Three Months Ended | Six Months Ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Reconciliation of GAAP to |
||||||||||||||||
$ | 36,783 | $ | 29,554 | $ | 84,436 | $ | 55,668 | |||||||||
Less: Stock-based compensation expense | (7,527 | ) | (1,659 | ) | (19,044 | ) | (3,350 | ) | ||||||||
$ | 29,256 | $ | 27,895 | $ | 65,392 | $ | 52,318 | |||||||||
Reconciliation of GAAP to Non-GAAP General and administrative: | ||||||||||||||||
GAAP General and administrative | $ | 16,600 | $ | 11,706 | $ | 37,387 | $ | 21,744 | ||||||||
Less: Stock-based compensation expense | (7,269 | ) | (2,824 | ) | (15,060 | ) | (5,360 | ) | ||||||||
Non-GAAP General and administrative | $ | 9,331 | $ | 8,882 | $ | 22,327 | $ | 16,384 | ||||||||
Reconciliation of GAAP to Non-GAAP Operating expenses: | ||||||||||||||||
GAAP Operating expenses | $ | 53,667 | $ | 41,492 | $ | 122,385 | $ | 77,813 | ||||||||
Less: Stock-based compensation expense | (14,796 | ) | (4,483 | ) | (34,104 | ) | (8,710 | ) | ||||||||
Non-GAAP Operating expenses | $ | 38,871 | $ | 37,009 | $ | 88,281 | $ | 69,103 | ||||||||
Reconciliation of GAAP to Non-GAAP Net loss: | ||||||||||||||||
GAAP Net loss | $ | (67,581 | ) | $ | (34,380 | ) | $ | (116,520 | ) | $ | (63,534 | ) | ||||
Add: Stock-based compensation expense | 14,796 | 4,483 | 34,104 | 8,710 | ||||||||||||
Add: Loss on extinguishment of debt | 11,183 | – | 11,183 | – | ||||||||||||
Add: Non-cash interest expense from liability related to sale of future royalties |
664 | – | 664 | – | ||||||||||||
Non-GAAP Net loss | $ | (40,938 | ) | $ | (29,897 | ) | $ | (70,569 | ) | $ | (54,824 | ) | ||||
Reconciliation of GAAP to Non-GAAP Net loss per common share-basic and diluted: |
||||||||||||||||
GAAP Net loss per common share-basic and diluted | $ | (2.03 | ) | $ | (1.14 | ) | $ | (3.51 | ) | $ | (2.12 | ) | ||||
Add: Stock-based compensation expense | 0.44 | 0.15 | 1.03 | 0.29 | ||||||||||||
Add: Loss on extinguishment of debt | 0.34 | – | 0.34 | – | ||||||||||||
Add: Non-cash interest expense from liability related to sale of future royalties |
0.02 | – | 0.02 | – | ||||||||||||
Non-GAAP Net loss per common share-basic and diluted | $ | (1.23 | ) | $ | (0.99 | ) | $ | (2.12 | ) | $ | (1.83 | ) | ||||
Three Months Ended | ||||||||||||
Reconciliation of GAAP to Non-GAAP Operating expenses |
||||||||||||
GAAP – Operating expenses | $ | 53,667 | $ | 68,718 | $ | 187,103 | ||||||
Less: Stock-based compensation expense | (14,796 | ) | (19,307 | ) | (12,291 | ) | ||||||
Less: Reacquired license rights expense | – | – | (124,398 | ) | ||||||||
Non – GAAP – Operating expenses | $ | 38,871 | $ | 49,411 | $ | 50,414 | ||||||
Reconciliation of GAAP to Non-GAAP Net loss | ||||||||||||
GAAP – Net loss | $ | (67,581 | ) | $ | (48,939 | ) | $ | (186,942 | ) | |||
Add: Stock-based compensation expense | 14,796 | 19,307 | 12,291 | |||||||||
Add: Loss on extinguishment of debt | 11,183 | – | – | |||||||||
Add: Non-cash interest expense from liability related to sale of future royalties |
664 | – | – | |||||||||
Add: Reacquired license rights expense | – | – | 124,398 | |||||||||
Non-GAAP Net loss | $ | (40,938 | ) | $ | (29,632 | ) | $ | (50,253 | ) | |||
Source: Reata Pharmaceuticals, Inc.